Patents by Inventor Stephane Hubert Olland

Stephane Hubert Olland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120014975
    Abstract: The invention relates to modified single domain antigen binding molecules, e.g., SDAB molecules, in particular TNF?-binding SDAB molecules. Method of preparing, and using the modified single domain antigen binding molecules described herein, to treat, e.g., TNF?-associated disorders, are also disclosed.
    Type: Application
    Filed: July 14, 2011
    Publication date: January 19, 2012
    Applicant: Wyeth LLC
    Inventors: Martin Hegen, Stephane Hubert Olland, Yulia Vugmeyster, Xin Xu
  • Patent number: 7625731
    Abstract: This invention relates to aggrecanase polypeptides and aggrecanase polypeptide/ligand complexes, crystals of aggrecanase and aggrecanase polypeptide/ligand complexes, and related methods and software systems.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: December 1, 2009
    Assignee: Wyeth
    Inventors: Lydia Mosyak, Thomas Saltmarsh Rush, III, Stephane Hubert Olland, Edward R. LaVallie, Lisa A. Collins-Racie, Christopher John Corcoran, Stewart Andrews Mackie
  • Patent number: 7615363
    Abstract: This invention relates to aggrecanase polypeptides and aggrecanase polypeptide/ligand complexes, crystals of aggrecanase and aggrecanase polypeptide/ligand complexes, and related methods and software systems.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: November 10, 2009
    Assignee: Wyeth
    Inventors: Lidia Mosyak, Thomas Saltmarsh Rush, III, Xiaotian Zhong, Thomas E. McDonagh, Katy E. Georgiadis, Phaik-Eng Sum, Edward R. LaVallie, Lisa A. Collins-Racie, Christopher John Corcoran, Ravindra Kumar, Tracy Hebert, Stephane Hubert Olland, Stewart Andrews Mackie
  • Publication number: 20040091908
    Abstract: This invention is directed to the crystal structures of Kv channel proteins, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of Kv channel proteins. Such agents may be useful as therapeutic agents.
    Type: Application
    Filed: July 1, 2003
    Publication date: May 13, 2004
    Inventors: Weixin Xu, Zhangbao Xu, Laura Long Lin, Stephane Hubert Olland, Lidia Mosyak, William Stuart Somers